Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
Background: Ruxolitinib is a potent inhibitor of JAK1/2 with proven efcacy in myelofbrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have shown signifcant responses in refractory GVHD p...
| Autores: | , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2017 |
| País: | España |
| Institución: | Universidad de Sevilla (US) |
| Repositorio: | idUS. Depósito de Investigación de la Universidad de Sevilla |
| OAI Identifier: | oai:idus.us.es:11441/157707 |
| Acceso en línea: | https://hdl.handle.net/11441/157707 https://doi.org/10.1186/s40164-017-0092-3 |
| Access Level: | acceso abierto |
| Palabra clave: | Ruxolitinib Graft versus host disease Corticoid refractoriness Extracorporeal photopheresis |
| Sumario: | Background: Ruxolitinib is a potent inhibitor of JAK1/2 with proven efcacy in myelofbrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have shown signifcant responses in refractory GVHD patients. Cases presentation: In this report we present our experience in 8 patients with acute or chronic GVHD with refrac‑ toriness to steroids and extracorporeal photopheresis treated with ruxolitinib. Three patients had acute GVHD (1 pulmonary, 2 cutaneous, 1 multi-systemic) and 5 had chronic GVHD (3 cutaneous); 85% obtained an overall response and 50% a complete response with a tolerable toxicity profle. Conclusions: In our series, Ruxolitinib was very active as a rescue therapy for patients with acute or chronic GVHD refractory to standard treatment |
|---|